Ki = 1.6 nM for MCT1
AZD 3965 is a potent inhibitor of monocarboxylate transporter 1 (MCT1).
Inhibition of monocarboxylate transporter 1 (MCT1) is currently considered as a promosing therapeutic way to block lactate shuttling in tumor cells lacking monocarboxylate transporter 4.
In vitro: Previous study found that the in-vitro AZD3965 sensitivity varied and was highest in hypoxia. To further support that AZD3965 targeted MCT1, NCIH1048 cells were engineered to inducibly overexpress MCT1. It was found that when MCT1 was overexpressed, the EC50 of AZD 3965 against NCI-H1048 was increased from 0.14 to 10.5 nM, which was consistent with AZD3965 acting through MCT1 inhibition [1].
In vivo: COR-L103 xenograft studies were conducted to test whether the in-vitro effect of AZD3965 could be recapitulated in vivo. COR-L103 tumor-bearing mice were treated with AZD3965 at 100 mg/kg BID for 21 days. The pharmacokinetic analyses showed that AZD3965 at 100 mg/kg BID led to free concentrations of AZD3965 predicted to inhibit lactate transport. Moreover, AZD3965 treatment was able to reduce the growth of CORL103 tumors significantly, though tumor regression was not observed, which was consistent with AZD3965 only targeting the hypoxic fraction of the tumor [1].
Clinical trial: A phase I trial of AZD3965 in patients with advanced cancer is currently recruiting participants [2].
References:
[1] Polanski, R. ,Hodgkinson, C.L.,Fusi, A., et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin.Cancer.Res 20(4), (2014).
[2] https://clinicaltrials. gov/ct2/show/NCT01791595 term=AZD+3965&rank=1
MCT1 的 Ki = 1.6 nM
AZD 3965 是单羧酸转运蛋白 1 (MCT1) 的有效抑制剂。
抑制单羧酸转运蛋白 1 (MCT1) 目前被认为是一种促进缺乏单羧酸转运蛋白 4 的肿瘤细胞中乳酸穿梭的治疗方法。
体外:先前的研究发现体外 AZD3965 敏感性不同,在缺氧条件下最高。为了进一步支持 AZD3965 以 MCT1 为靶点,NCIH1048 细胞被设计为诱导性过表达 MCT1。结果发现,当 MCT1 过表达时,AZD 3965 对 NCI-H1048 的 EC50 从 0.14 增加到 10.5 nM,这与 AZD3965 通过 MCT1 抑制作用一致 [1]。
体内:COR -L103 异种移植研究是为了测试 AZD3965 的体外作用是否可以在体内重现。用 100 mg/kg BID 的 AZD3965 处理 COR-L103 荷瘤小鼠 21 天。药代动力学分析表明,100 mg/kg BID 的 AZD3965 导致预测抑制乳酸转运的 AZD3965 游离浓度。此外,AZD3965 治疗能够显着减少 CORL103 肿瘤的生长,但未观察到肿瘤消退,这与 AZD3965 仅靶向肿瘤缺氧部分一致 [1]。
临床试验:AZD3965在晚期癌症患者中的I期试验目前正在招募参与者[2]。
















